Johnson & Johnson’s COVID-19 vaccine.Photo: Alex Gottschalk/DeFodi Images via GettyTheJohnson & Johnsonsingle-dose vaccine can now provide immunity againstCOVID-19for at least eight months, as well as protection against “other highly prevalent SARS-CoV-2 viral variants” of the virus.The companyannounced on Thursdaythat during its trial, the vaccine generated a “strong neutralizing antibody response” to the widely spreading Delta variant, with 85% effectiveness.It is also expected to improve and continue immunity past the eight-month span of their study — reassuring the over 12 million Americans who have gottenthe Johnson & Johnson dose.“Current data for the eight months studied so far show that the single-shot Johnson & Johnson COVID-19 vaccine generates a strong neutralizing antibody response that does not wane; rather, we observe an improvement over time,” said Mathai Mammen, global head, Janssen research & development, Johnson & Johnson, in a statement.Never miss a story — sign up forPEOPLE’s free daily newsletterto stay up-to-date on the best of what PEOPLE has to offer, from juicy celebrity news to compelling human-interest stories.“In addition, we observe a persistent and particularly robust, durable cellular immune response,” Mammen added.The Johnson & Johnson study follows the lead of Moderna and Pfizer after the biotech companies also announced that their vaccines areextremely effective against the variant, preventing illness 90% of the time and hospitalization or severe illness 94% of the time.The Delta variant currently makes up over 20% of all COVID-19 cases, and ispresent in all 50 states. Health experts are concerned the highly contagious strain will continue spreading, especially among unvaccinated people.“The Delta variant is currently the greatest threat in the U.S. to our attempt to eliminate COVID-19,“Dr. Anthony Fauci, the nation’s top infectious diseases expert, said during a White House briefing last month.RELATED VIDEO: The Importance of the COVID-19 Vaccine and the Call for “Unity"Fauci, 80, added Tuesday that he’s"very concerned” about the Delta variant spreadingin under-vaccinated, high-risk areas, and said it could split the country into “two Americas”: one in which the virus is circulating widely and the other with low rates because most residents are vaccinated.“When you havesuch a low level of vaccinationsuperimposed upon a variant that has a high degree of efficiency of spread, what you are going to see among under-vaccinated regions — be that states, cities or counties — you’re going to see these individual types of blips,” he said,CNN reported. “It’s almost like it’s going to be two Americas.“As of Thursday, nearly 181.4 million Americans (just below 55% of the total population) have received at least one vaccine dose and 155.9 million (47%) are fully vaccinated, according to theCenters for Disease Control.As information about thecoronavirus pandemicrapidly changes, PEOPLE is committed to providing the most recent data in our coverage. Some of the information in this story may have changed after publication. For the latest on COVID-19, readers are encouraged to use online resources from theCDC,WHOandlocal public health departments.PEOPLE has partnered with GoFundMeto raise money for the COVID-19 Relief Fund, a GoFundMe.org fundraiser to support everything from frontline responders to families in need, as well as organizations helping communities. For more information or to donate, clickhere.
Johnson & Johnson’s COVID-19 vaccine.Photo: Alex Gottschalk/DeFodi Images via Getty
TheJohnson & Johnsonsingle-dose vaccine can now provide immunity againstCOVID-19for at least eight months, as well as protection against “other highly prevalent SARS-CoV-2 viral variants” of the virus.The companyannounced on Thursdaythat during its trial, the vaccine generated a “strong neutralizing antibody response” to the widely spreading Delta variant, with 85% effectiveness.It is also expected to improve and continue immunity past the eight-month span of their study — reassuring the over 12 million Americans who have gottenthe Johnson & Johnson dose.“Current data for the eight months studied so far show that the single-shot Johnson & Johnson COVID-19 vaccine generates a strong neutralizing antibody response that does not wane; rather, we observe an improvement over time,” said Mathai Mammen, global head, Janssen research & development, Johnson & Johnson, in a statement.Never miss a story — sign up forPEOPLE’s free daily newsletterto stay up-to-date on the best of what PEOPLE has to offer, from juicy celebrity news to compelling human-interest stories.“In addition, we observe a persistent and particularly robust, durable cellular immune response,” Mammen added.The Johnson & Johnson study follows the lead of Moderna and Pfizer after the biotech companies also announced that their vaccines areextremely effective against the variant, preventing illness 90% of the time and hospitalization or severe illness 94% of the time.The Delta variant currently makes up over 20% of all COVID-19 cases, and ispresent in all 50 states. Health experts are concerned the highly contagious strain will continue spreading, especially among unvaccinated people.“The Delta variant is currently the greatest threat in the U.S. to our attempt to eliminate COVID-19,“Dr. Anthony Fauci, the nation’s top infectious diseases expert, said during a White House briefing last month.RELATED VIDEO: The Importance of the COVID-19 Vaccine and the Call for “Unity"Fauci, 80, added Tuesday that he’s"very concerned” about the Delta variant spreadingin under-vaccinated, high-risk areas, and said it could split the country into “two Americas”: one in which the virus is circulating widely and the other with low rates because most residents are vaccinated.“When you havesuch a low level of vaccinationsuperimposed upon a variant that has a high degree of efficiency of spread, what you are going to see among under-vaccinated regions — be that states, cities or counties — you’re going to see these individual types of blips,” he said,CNN reported. “It’s almost like it’s going to be two Americas.“As of Thursday, nearly 181.4 million Americans (just below 55% of the total population) have received at least one vaccine dose and 155.9 million (47%) are fully vaccinated, according to theCenters for Disease Control.As information about thecoronavirus pandemicrapidly changes, PEOPLE is committed to providing the most recent data in our coverage. Some of the information in this story may have changed after publication. For the latest on COVID-19, readers are encouraged to use online resources from theCDC,WHOandlocal public health departments.PEOPLE has partnered with GoFundMeto raise money for the COVID-19 Relief Fund, a GoFundMe.org fundraiser to support everything from frontline responders to families in need, as well as organizations helping communities. For more information or to donate, clickhere.
TheJohnson & Johnsonsingle-dose vaccine can now provide immunity againstCOVID-19for at least eight months, as well as protection against “other highly prevalent SARS-CoV-2 viral variants” of the virus.
The companyannounced on Thursdaythat during its trial, the vaccine generated a “strong neutralizing antibody response” to the widely spreading Delta variant, with 85% effectiveness.
It is also expected to improve and continue immunity past the eight-month span of their study — reassuring the over 12 million Americans who have gottenthe Johnson & Johnson dose.
“Current data for the eight months studied so far show that the single-shot Johnson & Johnson COVID-19 vaccine generates a strong neutralizing antibody response that does not wane; rather, we observe an improvement over time,” said Mathai Mammen, global head, Janssen research & development, Johnson & Johnson, in a statement.
Never miss a story — sign up forPEOPLE’s free daily newsletterto stay up-to-date on the best of what PEOPLE has to offer, from juicy celebrity news to compelling human-interest stories.
“In addition, we observe a persistent and particularly robust, durable cellular immune response,” Mammen added.
The Johnson & Johnson study follows the lead of Moderna and Pfizer after the biotech companies also announced that their vaccines areextremely effective against the variant, preventing illness 90% of the time and hospitalization or severe illness 94% of the time.
The Delta variant currently makes up over 20% of all COVID-19 cases, and ispresent in all 50 states. Health experts are concerned the highly contagious strain will continue spreading, especially among unvaccinated people.
“The Delta variant is currently the greatest threat in the U.S. to our attempt to eliminate COVID-19,“Dr. Anthony Fauci, the nation’s top infectious diseases expert, said during a White House briefing last month.
RELATED VIDEO: The Importance of the COVID-19 Vaccine and the Call for “Unity”
Fauci, 80, added Tuesday that he’s"very concerned” about the Delta variant spreadingin under-vaccinated, high-risk areas, and said it could split the country into “two Americas”: one in which the virus is circulating widely and the other with low rates because most residents are vaccinated.
“When you havesuch a low level of vaccinationsuperimposed upon a variant that has a high degree of efficiency of spread, what you are going to see among under-vaccinated regions — be that states, cities or counties — you’re going to see these individual types of blips,” he said,CNN reported. “It’s almost like it’s going to be two Americas.”
As of Thursday, nearly 181.4 million Americans (just below 55% of the total population) have received at least one vaccine dose and 155.9 million (47%) are fully vaccinated, according to theCenters for Disease Control.
As information about thecoronavirus pandemicrapidly changes, PEOPLE is committed to providing the most recent data in our coverage. Some of the information in this story may have changed after publication. For the latest on COVID-19, readers are encouraged to use online resources from theCDC,WHOandlocal public health departments.PEOPLE has partnered with GoFundMeto raise money for the COVID-19 Relief Fund, a GoFundMe.org fundraiser to support everything from frontline responders to families in need, as well as organizations helping communities. For more information or to donate, clickhere.
source: people.com
